Valacyclovir in Neonatal Herpes Simplex Virus Disease
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 7 people enrolled
- Started
- 1 Jul 2021
- Ended
- 24 Jul 2024
- Type of study
- Interventional
- Treatments tested
- Valacyclovir
- Record updated
- 24 June 2025
Who can take part
- Age
- 2 weeks to 12 weeks
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Signed informed consent from parent(s) or legal guardian(s)
- Confirmation of HSV infection from surface culture/PCR, skin lesion culture/PCR, blood PCR, or CSF PCR (performed at UAB Virology lab)
- ≥34 weeks gestational age at birth
- Weight at study enrollment is ≥ 2000 grams
- Receiving intravenous acyclovir, prescribed by the patient's physician for ≤ 14 days
- ≤ 42 days of age at initiation of parenteral acyclovir
- Creatinine ≤ 1.2
Who cannot take part
- Current receipt of other investigational drugs
- Major congenital anomaly that in the site investigator's opinion may impact drug metabolism or the patient's volume of distribution
- Evidence of immunosuppression (HIV infected, immune deficiencies, etc.)
- Any condition that, in the opinion of the investigator, would place the subject at an unacceptable injury risk or that may interfere with successful study completion
- Creatinine of > 1.2 prior to initiation of valacyclovir
- > 42 days of age at initiation of parenteral acyclovir
- Imminent demise
- Concern for parental/guardian compliance
Where in United States
- University of Alabama/Children's of AlabamaBirmingham, United States
About the trial
What the trial wants to find out
This is an open-label, single center, pharmacokinetic (PK) study to assess valacyclovir pharmacokinetics and pharmacodynamics in neonates and compare to the pharmacokinetics and pharmacodynamics of the standard of care treatment dose of intravenous acyclovir. 6 (up to 10 infants) with virologically confirmed neonatal herpes simplex virus (HSV) disease who meet all inclusion/exclusion criteria will be enrolled in the study. Study duration is 5 years. Primary objective is to define the pharmacokinetics of valacyclovir and assess its safety in neonates 2-12 weeks of age who are ≥ 34 weeks gestation.
The group in the trial
- Neonatal HSV disease requiring suppressive therapyOther group
All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.
Treatment: Valacyclovir
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Pharmacokinetics and Pharmacodynamics of Valacyclovir in Neonates With Neonatal Herpes Simplex Virus Disease Who Have Completed Standard of Care Treatment With Acyclovir
- Record updated
- 24 June 2025